1
|
Leivonen SK, Friman T, Autio M, Vaittinen S, Jensen AW, D'Amore F, Hamilton-Dutoit SJ, Holte H, Beiske K, Kovanen PE, Räty R, Leppä S. Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas. Haematologica 2023; 108:3044-3057. [PMID: 37259566 PMCID: PMC10620595 DOI: 10.3324/haematol.2023.282831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Accepted: 05/23/2023] [Indexed: 06/02/2023] Open
Abstract
Post-transplant lymphoproliferative disorders (PTLD) are iatrogenic immune deficiency-associated lymphoid/plasmacytic proliferations developing due to immunosuppression in solid organ or hematopoietic stem cell allograft patients. PTLD are characterized by abnormal proliferation of lymphoid cells and have a heterogeneous clinical behavior. We profiled expression of >700 tumor microenvironment (TME)-related genes in 75 post-transplant aggressive B-cell lymphomas (PTABCL). Epstein-Barr virus (EBV)-positive PT-ABCL clustered together and were enriched for type I interferon pathway and antiviral-response genes. Additionally, a cytotoxicity gene signature associated with EBV-positivity and favorable overall survival (OS) (hazard ratio =0.61; P=0.019). In silico immunophenotyping revealed two subgroups with distinct immune cell compositions. The inflamed subgroup with higher proportions of immune cells had better outcome compared to noninflamed subgroup (median OS >200.0 vs. 15.2 months; P=0.006). In multivariable analysis with EBV status, International Prognostic Index, and rituximab-containing treatment, inflamed TME remained as an independent predictor for favorable outcome. We also compared TME between post-transplant and immunocompetent host diffuse large B-cell lymphomas (n=75) and discovered that the proportions of T cells were lower in PT-diffuse large B-cell lymphomas. In conclusion, we provide a comprehensive phenotypic characterization of PT-ABCL, highlighting the importance of immune cell composition of TME in determining the clinical behavior and prognosis of PT-ABCL.
Collapse
Affiliation(s)
- Suvi-Katri Leivonen
- Applied Tumor Genomics Research Program, Medical Faculty, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki
| | - Terhi Friman
- Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki
| | - Matias Autio
- Applied Tumor Genomics Research Program, Medical Faculty, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki
| | - Samuli Vaittinen
- Department of Pathology, Turku University Hospital, University of Turku, Turku
| | | | | | | | - Harald Holte
- Department of Oncology, Oslo University Hospital, Oslo, Norway
| | - Klaus Beiske
- Department of Pathology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
| | - Panu E Kovanen
- Department of Pathology, University of Helsinki, and HUSLAB, Helsinki University Hospital, Helsinki
| | - Riikka Räty
- Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki
| | - Sirpa Leppä
- Applied Tumor Genomics Research Program, Medical Faculty, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki.
| |
Collapse
|
2
|
Antiga E, Bech R, Maglie R, Genovese G, Borradori L, Bockle B, Caproni M, Caux F, Chandran NS, Corrà A, D'Amore F, Daneshpazhooh M, De D, Didona D, Dmochowski M, Drenovska K, Ehrchen J, Feliciani C, Goebeler M, Groves R, Günther C, Handa S, Hofmann SC, Horvath B, Ioannidis D, Jedlickova H, Kowalewski C, Kridin K, Joly P, Lim YL, Marinovic B, Maverakis E, Meijer J, Patsatsi A, Pincelli C, Prost C, Setterfield J, Sprecher E, Skiljevic D, Tasanen K, Uzun S, Van Beek N, Vassileva S, Vorobyev A, Vujic I, Wang G, Wang M, Wozniak K, Yayli S, Zambruno G, Hashimoto T, Schmidt E, Mascarò JM, Marzano AV. Corrigendum: S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2023; 37:2378-2379. [PMID: 37702229 DOI: 10.1111/jdv.19489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/14/2023]
Affiliation(s)
- Emiliano Antiga
- Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
| | - Rikke Bech
- Department of Dermatology and Venerology, Aarhus University Hospital, Aarhus, Denmark
| | - Roberto Maglie
- Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
| | - Giovanni Genovese
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Luca Borradori
- Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Barbara Bockle
- Department of Dermatology, Venereology and Allergology, Innsbruck Medical University, Innsbruck, Austria
| | - Marzia Caproni
- Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
- Rare Diseases Unit, Azienda USL Toscana Centro, European Reference Network Skin Member, Florence, Italy
| | - Frédéric Caux
- Department of Dermatology, Groupe Hospitalier Paris-Seine-Saint-Denis, AP-HP, Bobigny, France
| | - Nisha Suyien Chandran
- Division of Dermatology, Department of Medicine, National University Hospital, Singapore, Singapore
- Department of Medicine, NUS Yong Loo Lin School of Medicine, Singapore, Singapore
| | - Alberto Corrà
- Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
| | - Francesco D'Amore
- Department of Haematology, University Hospital of Aarhus, Aarhus, Denmark
| | - Maryam Daneshpazhooh
- Autoimmune Bullous diseases Research Center, Department of Dermatology, Razi Hospital, University of Medical Sciences, Tehran, Iran
| | - Dipankar De
- Department of Dermatology, PGIMER, Chandigarh, India
| | - Dario Didona
- Department of Dermatology and Allergology, Philipps University, Marburg, Germany
| | - Marian Dmochowski
- Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, Poznań, Poland
| | - Kossara Drenovska
- Department of Dermatology and Venereology, Medical Faculty, Medical University, Sofia, Bulgaria
| | - Jan Ehrchen
- Department of Dermatology, University of Münster, Münster, Germany
| | - Claudio Feliciani
- Section of Dermatology, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
| | - Matthias Goebeler
- Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany
| | - Richard Groves
- Clinical Immunodermatology, St. John's Institute of Dermatology Guy's Hospital, Great Maze Pond, London, UK
| | - Claudia Günther
- Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - Sanjeev Handa
- Department of Dermatology, Venereology & Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Silke C Hofmann
- Department of Dermatology, Allergy and Dermatosurgery, Helios University Hospital, University Witten/Herdecke, Wuppertal, Germany
| | - Barbara Horvath
- Department of Dermatology, Expertise Center for Blistering Disease, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Dimitrios Ioannidis
- 1st Department of Dermatology-Venereology, Aristotle University School of Medicine, Thessaloniki, Greece
| | - Hana Jedlickova
- Department of Dermatovenereology, St. Anna Hospital, Masaryk University, Brno, Czech Republic
| | - Cezary Kowalewski
- Department Dermatology and Immunodermatology, Medical University of Warsaw, Warsaw, Poland
| | - Khalaf Kridin
- Unit of Dermatology and Skin Research Laboratory, Baruch Padeh Medical Center, Poriya, Israel
- Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
| | - Pascal Joly
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de Référence des Maladies Bulleuses Autoimmunes, Normandie University, Rouen, France
| | - Yen Loo Lim
- National Skin Centre, Singapore, Singapore
- Yong Loo Lin School of Medicine, Lee Kong Chian School of Medicine, Duke-NUS, Singapore, Singapore
| | - Branka Marinovic
- University Hospital Center Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Emanual Maverakis
- Department of Dermatology, University of California Davis, Sacramento, California, USA
| | - Joost Meijer
- Department of Dermatology, Expertise Center for Blistering Disease, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Aikaterini Patsatsi
- Autoimmune Bullous Diseases Unit, 2nd Dermatology Department, Aristotle University School of Medicine, Thessaloniki, Greece
| | - Carlo Pincelli
- DermoLab, Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Catherine Prost
- Department of Dermatology and Referral Center for Autoimmune Bullous Diseases (MALIBUL), Avicenne University Hospital, Hôpitaux Universitaires de Paris Seine-Saint-Denis (HUPSSD), Assistance Publique - Hôpitaux de Paris (AP-HP), Université Sorbonne Paris Nord (USPN), Bobigny, France
| | - Jane Setterfield
- Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, London, UK
| | - Eli Sprecher
- Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
| | - Dusan Skiljevic
- Department of Dermatovenereology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- Clinic of Dermatovenereology, University Clinical Center of Serbia, Belgrade, Serbia
| | - Kaisa Tasanen
- PEDEGO Research Unit, Department of Dermatology, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
| | - Soner Uzun
- Department of Dermatology and Venereology, Akdeniz University Faculty of Medicine, Antalya, Turkey
| | - Nina Van Beek
- Department of Dermatology, University of Lübeck, Lübeck, Germany
| | - Snejina Vassileva
- Department of Dermatology and Venereology, Medical Faculty, Medical University, Sofia, Bulgaria
| | - Artem Vorobyev
- Department of Dermatology, University of Lübeck, Lübeck, Germany
| | - Igor Vujic
- Department of Dermatology, Klinik Landstraße, Vienna, Austria
- Faculty of Medicine and Dentistry, Danube Private University, Krems, Austria
| | - Gang Wang
- Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China
| | - Mingyue Wang
- Department of Dermatology, Peking University First Hospital, Beijing, China
- National Clinical Research Center for Skin and Immune Diseases, Beijing, China
| | - Katarzyna Wozniak
- Department of Dermatology, Immunodermatology and Venereology, Medical University of Warsaw, Warsaw, Poland
| | - Savas Yayli
- Department of Dermatology, Koç University School of Medicine, Istanbul, Turkey
| | - Giovanna Zambruno
- Genodermatosis Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Takashi Hashimoto
- Department of Dermatology, Osaka Metroplitan University Graduate School of Medicine, Osaka, Japan
| | - Enno Schmidt
- Department of Dermatology, University of Lübeck, Lübeck, Germany
- Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany
| | - José Manuel Mascarò
- Department of Dermatology, Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain
| | - Angelo Valerio Marzano
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
| |
Collapse
|
3
|
Martino M, Tassone A, Angiuli L, Naccarato A, Dambruoso PR, Mazzone F, Trizio L, Leonardi C, Petracchini F, Sprovieri F, Pirrone N, D'Amore F, Bencardino M. First atmospheric mercury measurements at a coastal site in the Apulia region: seasonal variability and source analysis. Environ Sci Pollut Res Int 2022; 29:68460-68475. [PMID: 35543786 PMCID: PMC9508219 DOI: 10.1007/s11356-022-20505-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Accepted: 04/25/2022] [Indexed: 06/15/2023]
Abstract
In the framework of the Italian Special Network for Mercury (ISNM) "Reti Speciali", a sampling campaign to monitor atmospheric mercury (Hg) was carried out at Monte Sant'Angelo (MSA). This is a coastal monitoring station in the Apulia region, representative of the Southern Adriatic area, within the Mediterranean basin. This work presents continuous Gaseous Elemental Mercury (GEM) measurements over about three years at MSA, using the Lumex RA-915AM mercury analyzer. The aim was to obtain a dataset suitable for the analysis of Hg concentrations in terms of source and transport variation. Diurnal cycles of GEM were evaluated to observe the influence of local atmospheric temperature and wind speed on potential re-emissions from surrounding sea and soil surfaces. Data were also analyzed in terms of long-range transport, using backward trajectory cluster analysis. The spatial distribution of potential sources, contributing to higher measured GEM values, was obtained employing Potential Source Contribution Function (PSCF) statistics. The influence of major Hg anthropogenic point sources, such as mining activities and coal-fuel power plants, both regionally and continentally, from mainland Europe, was observed. The role of the vegetation GEM uptake in modulating the seasonal GEM variability was also investigated. The potential of wildfire influence over the highest detected GEM levels was further examined using active fire data and the evaluation of the vegetation dryness index during the selected episodes.
Collapse
Affiliation(s)
- Maria Martino
- CNR-Institute of Atmospheric Pollution Research, Rende, Italy
| | | | - Lorenzo Angiuli
- Apulia Region Environmental Protection Agency (ARPA Puglia), Bari, Italy
| | - Attilio Naccarato
- CNR-Institute of Atmospheric Pollution Research, Rende, Italy
- Department of Chemistry and Chemical Technologies, University of Calabria, Rende, Italy
| | | | - Fiorella Mazzone
- Apulia Region Environmental Protection Agency (ARPA Puglia), Bari, Italy
| | - Livia Trizio
- Apulia Region Environmental Protection Agency (ARPA Puglia), Bari, Italy
| | | | | | | | - Nicola Pirrone
- CNR-Institute of Atmospheric Pollution Research, Rende, Italy
| | | | | |
Collapse
|
4
|
Lombardi N, Sorrentino D, D'Amore F, Francischini R, Lodi G. Granuloma piogenico linguale in gravidanza: un case report. Dental Cadmos 2021. [DOI: 10.19256/d.cadmos.2021.35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
5
|
Vajavaara H, Ekeblad F, Holte H, Jorgensen J, Leivonen SK, Berglund M, Kamper P, Moller HJ, D'Amore F, Molin D, Enblad G, Ludvigsen M, Glimelius I, Leppa S. Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma. Haematologica 2021; 106:2502-2506. [PMID: 33764002 PMCID: PMC8409034 DOI: 10.3324/haematol.2020.278182] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Indexed: 11/09/2022] Open
Affiliation(s)
- Heli Vajavaara
- Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki
| | - Frida Ekeblad
- Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala
| | - Harald Holte
- Department of Oncology and KG Jebsen center for B-cell malignancies, Oslo University Hospital, Oslo
| | - Judit Jorgensen
- Department of Hematology, Aarhus University Hospital, Aarhus
| | - Suvi-Katri Leivonen
- Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki
| | - Mattias Berglund
- Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala
| | - Peter Kamper
- Department of Hematology, Aarhus University Hospital, Aarhus
| | - Holger J Moller
- Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus
| | - Francesco D'Amore
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus
| | - Daniel Molin
- Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala
| | - Gunilla Enblad
- Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala
| | - Maja Ludvigsen
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus
| | - Ingrid Glimelius
- Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Department of Medicine, division of clinical epidemiology, Karolinska Institutet, Solna.
| | - Sirpa Leppa
- Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki.
| |
Collapse
|
6
|
Castagna J, Senatore A, Bencardino M, D'Amore F, Sprovieri F, Pirrone N, Mendicino G. Multiscale assessment of the impact on air quality of an intense wildfire season in southern Italy. Sci Total Environ 2021; 761:143271. [PMID: 33183815 DOI: 10.1016/j.scitotenv.2020.143271] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 09/23/2020] [Accepted: 10/18/2020] [Indexed: 06/11/2023]
Abstract
The summer of 2017 in the Calabria Region (South Italy) was an exceptional wildfire season with the largest area burned by wildfires in the last 11 years (2008-2019). The equivalent black carbon (EBC) and carbon monoxide (CO) measurements, recorded at the high-altitude Global Atmosphere Watch (GAW) Monte Curcio (MCU) regional station, were analyzed to establish the wildfires' impact on air quality, human health, and the ecosystem. A method was applied to identify the possible wildfires that influenced the air quality based on the integration of fire data (both satellite and ground-based) and the high-resolution WRF-HYSPLIT trajectories. The satellite-based fires applied to WRF-HYSPLIT with 10 km of spatial resolution allowed us to establish that for 52.5% of total cases, wildfires were located outside the Calabria Region, and they were influenced by long-range transport. Nonetheless, the impact on human health, qualitatively evaluated in terms of passively smoked cigarettes (PSC) corresponding to the EBC, was greater when wildfires were local. Indeed, for wildfires located mainly in Calabria, the equivalent PSC ranged from 2.75 to 11.08. This maximum PSC value was close to the daily number of smoked cigarettes in Calabria (approximately 12.4). Even if this analogy does not imply a proportional effect between the estimated number of cigarettes smoked and the effective wildfire EBC exposure, this result suggests that wildfire emissions may have negative effects on people's health. Moreover, a focus on the Calabria Region was conducted using high-resolution ground-based GPS and higher resolution WRF-HYSPLIT back-trajectories (2 km) to measure wildfires. The validity of the methodology was confirmed by the EBC and CO positive correlation with the ratio between the identified ground-based burned areas and the distance from the sampling station. Moreover, the impact on the ecosystem was studied by analyzing the land vegetation loss due to the wildfires that contributed to air quality reduction at the MCU station. A total of more than 1679 ha of vegetation burned, the main losses comprising forests and shrubland.
Collapse
Affiliation(s)
- Jessica Castagna
- Department of Environmental Engineering, University of Calabria, 87036 Rende, Cosenza, Italy.
| | - Alfonso Senatore
- Department of Environmental Engineering, University of Calabria, 87036 Rende, Cosenza, Italy
| | | | - Francesco D'Amore
- CNR-Institute of Atmospheric Pollution Research, 87036 Rende, Cosenza, Italy
| | - Francesca Sprovieri
- CNR-Institute of Atmospheric Pollution Research, 87036 Rende, Cosenza, Italy
| | - Nicola Pirrone
- CNR-Institute of Atmospheric Pollution Research, 87036 Rende, Cosenza, Italy
| | - Giuseppe Mendicino
- Department of Environmental Engineering, University of Calabria, 87036 Rende, Cosenza, Italy
| |
Collapse
|
7
|
D'Amore F, Grinberg F, Mauler J, Galldiks N, Blazhenets G, Farrher E, Filss C, Stoffels G, Mottaghy FM, Lohmann P, Shah NJ, Langen KJ. Combined 18F-FET PET and diffusion kurtosis MRI in posttreatment glioblastoma: differentiation of true progression from treatment-related changes. Neurooncol Adv 2021; 3:vdab044. [PMID: 34013207 PMCID: PMC8117449 DOI: 10.1093/noajnl/vdab044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Radiological differentiation of tumor progression (TPR) from treatment-related changes (TRC) in pretreated glioblastoma is crucial. This study aimed to explore the diagnostic value of diffusion kurtosis MRI combined with information derived from O-(2-[18F]-fluoroethyl)-l-tyrosine (18F-FET) PET for the differentiation of TPR from TRC in patients with pretreated glioblastoma. Methods Thirty-two patients with histomolecularly defined and pretreated glioblastoma suspected of having TPR were included in this retrospective study. Twenty-one patients were included in the TPR group, and 11 patients in the TRC group, as assessed by neuropathology or clinicoradiological follow-up. Three-dimensional (3D) regions of interest were generated based on increased 18F-FET uptake using a tumor-to-brain ratio of 1.6. Furthermore, diffusion MRI kurtosis maps were obtained from the same regions of interest using co-registered 18F-FET PET images, and advanced histogram analysis of diffusion kurtosis map parameters was applied to generated 3D regions of interest. Diagnostic accuracy was analyzed by receiver operating characteristic curve analysis and combinations of PET and MRI parameters using multivariate logistic regression. Results Parameters derived from diffusion MRI kurtosis maps show high diagnostic accuracy, up to 88%, for differentiating between TPR and TRC. Logistic regression revealed that the highest diagnostic accuracy of 94% (area under the curve, 0.97; sensitivity, 94%; specificity, 91%) was achieved by combining the maximum tumor-to-brain ratio of 18F-FET uptake and diffusion MRI kurtosis metrics. Conclusions The combined use of 18F-FET PET and MRI diffusion kurtosis maps appears to be a promising approach to improve the differentiation of TPR from TRC in pretreated glioblastoma and warrants further investigation.
Collapse
Affiliation(s)
- Francesco D'Amore
- Institute of Neuroscience and Medicine, Research Centre Juelich, Juelich, Germany.,Department of Neuroradiology, Circolo Hospital and Macchi Foundation, Varese, Italy
| | - Farida Grinberg
- Institute of Neuroscience and Medicine, Research Centre Juelich, Juelich, Germany
| | - Jörg Mauler
- Institute of Neuroscience and Medicine, Research Centre Juelich, Juelich, Germany
| | - Norbert Galldiks
- Institute of Neuroscience and Medicine, Research Centre Juelich, Juelich, Germany.,Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.,Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne and Duesseldorf, Germany
| | - Ganna Blazhenets
- Institute of Neuroscience and Medicine, Research Centre Juelich, Juelich, Germany.,Department of Nuclear Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Ezequiel Farrher
- Institute of Neuroscience and Medicine, Research Centre Juelich, Juelich, Germany
| | - Christian Filss
- Institute of Neuroscience and Medicine, Research Centre Juelich, Juelich, Germany.,Department of Nuclear Medicine, RWTH Aachen University, Aachen, Germany
| | - Gabriele Stoffels
- Institute of Neuroscience and Medicine, Research Centre Juelich, Juelich, Germany
| | - Felix M Mottaghy
- Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne and Duesseldorf, Germany.,Department of Nuclear Medicine, RWTH Aachen University, Aachen, Germany.,Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands.,Department of Stereotaxy and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Philipp Lohmann
- Institute of Neuroscience and Medicine, Research Centre Juelich, Juelich, Germany.,Department of Stereotaxy and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Nadim Jon Shah
- Institute of Neuroscience and Medicine, Research Centre Juelich, Juelich, Germany.,Department of Neurology, RWTH Aachen University, Aachen, Germany.,JARA-BRAIN-Translational Medicine, Aachen, Germany
| | - Karl-Josef Langen
- Institute of Neuroscience and Medicine, Research Centre Juelich, Juelich, Germany.,Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne and Duesseldorf, Germany.,Department of Nuclear Medicine, RWTH Aachen University, Aachen, Germany
| |
Collapse
|
8
|
Agosti E, Giorgianni A, D'Amore F, Vinacci G, Balbi S, Locatelli D. Is Guillain-Barrè syndrome triggered by SARS-CoV-2? Case report and literature review. Neurol Sci 2021; 42:607-612. [PMID: 32643136 PMCID: PMC7343406 DOI: 10.1007/s10072-020-04553-9] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2020] [Accepted: 07/02/2020] [Indexed: 01/27/2023]
Abstract
BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent responsible for coronavirus disease 2019 (COVID-19). Respiratory and gastrointestinal manifestations of SARS-CoV-2 are well described, less defined is the clinical neurological spectrum of COVID-19. We reported a case of COVID-19 patient with acute monophasic Guillain-Barré syndrome (GBS), and a literature review on the SARS-CoV-2 and GBS etiological correlation. CASE DESCRIPTION A 68 years-old man presented to the emergency department with symptoms of acute progressive symmetric ascending flaccid tetraparesis. Oropharyngeal swab for SARS-CoV-2 tested positive. Neurological examination showed bifacial nerve palsy and distal muscular weakness of lower limbs. The cerebrospinal fluid assessment showed an albuminocytologic dissociation. Electrophysiological studies showed delayed distal latencies and absent F waves in early course. A diagnosis of Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) subtype of GBS was then made. CONCLUSIONS Neurological manifestations of COVID-19 are still under study. The case we described of GBS in COVID-19 patient adds to those already reported in the literature, in support of SARS-CoV-2 triggers GBS. COVID-19 associated neurological clinic should probably be seen not as a corollary of classic respiratory and gastrointestinal symptoms, but as SARS-CoV-2-related standalone clinical entities. To date, it is essential for all Specialists, clinicians and surgeons, to direct attention towards the study of this virus, to better clarify the spectrum of its neurological manifestations.
Collapse
Affiliation(s)
- Edoardo Agosti
- Division of Neurosurgery, Department of Biotechnology and Life Sciences, University of Insubria, Via Guicciardini, 9, 21100, Varese, Italy.
| | - Andrea Giorgianni
- Department of Neuroradiology, ASST Sette Laghi, University of Insubria, Varese, Italy
| | - Francesco D'Amore
- Department of Neuroradiology, ASST Sette Laghi, University of Insubria, Varese, Italy
| | | | - Sergio Balbi
- Division of Neurosurgery, Department of Biotechnology and Life Sciences, University of Insubria, Via Guicciardini, 9, 21100, Varese, Italy
| | - Davide Locatelli
- Division of Neurosurgery, Department of Biotechnology and Life Sciences, University of Insubria, Via Guicciardini, 9, 21100, Varese, Italy
| |
Collapse
|
9
|
D'Amore F, Vinacci G, Agosti E, Cariddi LP, Terrana AV, Vizzari FA, Mauri M, Giorgianni A. Pressing Issues in COVID-19: Probable Cause to Seize SARS-CoV-2 for Its Preferential Involvement of Posterior Circulation Manifesting as Severe Posterior Reversible Encephalopathy Syndrome and Posterior Strokes. AJNR Am J Neuroradiol 2020; 41:1800-1803. [PMID: 32732268 DOI: 10.3174/ajnr.a6679] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Accepted: 06/03/2020] [Indexed: 12/11/2022]
Abstract
Since December 2019, a novel Severe Acute Respiratory Syndrome coronavirus 2 from China has rapidly spread worldwide. Although respiratory involvement is the mainstay of coronavirus disease 2019 (COVID-19), systemic involvement has recently drawn more attention. In particular, a number of recent articles have shed light on the nervous system as one of the possible targets. At our institution, we observed 15 patients with acute brain vascular manifestations; most interesting, we had a higher prevalence of the posterior circulation acute impairment. In our series, 7 patients had acute posterior cerebral injury: 1, hemorrhagic posterior reversible encephalopathy syndrome; 5, posterior circulation ischemic stroke; and 1, parieto-occipital hemorrhagic stroke. On the basis of our evidence and previous basic science reports, we believe a common etiopathogenetic thread may connect ischemic/hemorrhagic events of the posterior circulation and posterior reversible encephalopathy syndrome in the setting of COVID-19.
Collapse
Affiliation(s)
- F D'Amore
- From the Departments of Neuroradiology (F.D., A.V.T., F.A.V., A.G.)
| | | | - E Agosti
- Neurosurgery (E.A.), University of Insubria, Hospital of Circolo and Macchi Foundation, Varese, Lombardia, Italy
| | - L P Cariddi
- Neurology and Stroke Unit (L.P.C., M.M.), Hospital of Circolo and Macchi Foundation, Varese, Lombardia, Italy.,Clinical and Experimental Medical Humanities (L.P.C.), Center of Research in Medical Pharmacology, Univeristy of Insubria, Varese, Italy
| | - A V Terrana
- From the Departments of Neuroradiology (F.D., A.V.T., F.A.V., A.G.)
| | - F A Vizzari
- From the Departments of Neuroradiology (F.D., A.V.T., F.A.V., A.G.)
| | - M Mauri
- Neurology and Stroke Unit (L.P.C., M.M.), Hospital of Circolo and Macchi Foundation, Varese, Lombardia, Italy
| | - A Giorgianni
- From the Departments of Neuroradiology (F.D., A.V.T., F.A.V., A.G.)
| |
Collapse
|
10
|
Amador C, Greiner TC, Heavican TB, Smith LM, Galvis KT, Lone W, Bouska A, D'Amore F, Pedersen MB, Pileri S, Agostinelli C, Feldman AL, Rosenwald A, Ott G, Mottok A, Savage KJ, de Leval L, Gaulard P, Lim ST, Ong CK, Ondrejka SL, Song J, Campo E, Jaffe ES, Staudt LM, Rimsza LM, Vose J, Weisenburger DD, Chan WC, Iqbal J. Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. Blood 2019; 134:2159-2170. [PMID: 31562134 PMCID: PMC6908831 DOI: 10.1182/blood.2019000779] [Citation(s) in RCA: 94] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Accepted: 09/08/2019] [Indexed: 02/01/2023] Open
Abstract
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of mature T-cell malignancies; approximately one-third of cases are designated as PTCL-not otherwise specified (PTCL-NOS). Using gene-expression profiling (GEP), we have previously defined 2 major molecular subtypes of PTCL-NOS, PTCL-GATA3 and PTCL-TBX21, which have distinct biological differences in oncogenic pathways and prognosis. In the current study, we generated an immunohistochemistry (IHC) algorithm to identify the 2 subtypes in paraffin tissue using antibodies to key transcriptional factors (GATA3 and TBX21) and their target proteins (CCR4 and CXCR3). In a training cohort of 49 cases of PTCL-NOS with corresponding GEP data, the 2 subtypes identified by the IHC algorithm matched the GEP results with high sensitivity (85%) and showed a significant difference in overall survival (OS) (P = .03). The IHC algorithm classification showed high interobserver reproducibility among pathologists and was validated in a second PTCL-NOS cohort (n = 124), where a significant difference in OS between the PTCL-GATA3 and PTCL-TBX21 subtypes was confirmed (P = .003). In multivariate analysis, a high International Prognostic Index score (3-5) and the PTCL-GATA3 subtype identified by IHC were independent adverse predictors of OS (P = .0015). Additionally, the 2 IHC-defined subtypes were significantly associated with distinct morphological features (P < .001), and there was a significant enrichment of an activated CD8+ cytotoxic phenotype in the PTCL-TBX21 subtype (P = .03). The IHC algorithm will aid in identifying the 2 subtypes in clinical practice, which will aid the future clinical management of patients and facilitate risk stratification in clinical trials.
Collapse
Affiliation(s)
| | | | | | - Lynette M Smith
- Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE
| | - Karen Tatiana Galvis
- Department of Pathology and Microbiology and
- Department of Pathology and Laboratory Medicine, Fundacion Santa Fe de Bogota University Hospital, Bogota, Colombia
| | - Waseem Lone
- Department of Pathology and Microbiology and
| | | | - Francesco D'Amore
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
| | | | - Stefano Pileri
- European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
- Department of Specialized, Experimental and Diagnostic Medicine, University of Bologna, Bologna, Italy
| | - Claudio Agostinelli
- Department of Specialized, Experimental and Diagnostic Medicine, University of Bologna, Bologna, Italy
| | - Andrew L Feldman
- Department of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, MN
| | - Andreas Rosenwald
- Institute of Pathology and
- Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany
| | - German Ott
- Department of Clinical Pathology and
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Robert-Bosch-Krankenhaus, Stuttgart, Germany
| | - Anja Mottok
- Center for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada
- Institute of Human Genetics, Ulm University/University Medical Centre, Ulm, Germany
| | - Kerry J Savage
- Center for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - Laurence de Leval
- Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland
| | - Philippe Gaulard
- Département de Pathologie, Hôpital Henri-Mondor, Université Paris-Est, INSERM U955, Créteil, France
| | - Soon Thye Lim
- Division of Medical Oncology, National Cancer Centre Singapore/Duke-National University of Singapore (NUS) Medical School, Singapore
| | - Choon Kiat Ong
- Division of Medical Oncology, National Cancer Centre Singapore/Duke-National University of Singapore (NUS) Medical School, Singapore
| | | | - Joo Song
- Department of Pathology, City of Hope National Medical Center, Duarte, CA
| | - Elias Campo
- Hematopathology Unit, Hospital Clinic, Barcelona, Spain
- Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | | | - Louis M Staudt
- Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Lisa M Rimsza
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ; and
| | - Julie Vose
- Division of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE
| | | | - Wing C Chan
- Department of Pathology, City of Hope National Medical Center, Duarte, CA
| | | |
Collapse
|
11
|
Clausen MR, Maurer MJ, Ulrichsen SP, Larsen TS, Himmelstrup B, Rønnov-Jessen D, Link BK, Feldman AL, Slager SL, Nowakowski GS, Thompson CA, Pedersen PT, Madsen J, Pedersen RS, Gørløv JS, Cerhan JR, Nørgaard M, D'Amore F. Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. Clin Epidemiol 2019; 11:987-996. [PMID: 31814771 PMCID: PMC6861518 DOI: 10.2147/clep.s219595] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2019] [Accepted: 09/25/2019] [Indexed: 12/12/2022] Open
Abstract
Background Hemoglobin (Hgb) concentration at diagnosis is associated with outcome in cancer. In a recently reported simplified 3-factor prognostic score in Hodgkin lymphoma, Hgb, along with age and clinical stage, outperformed the classical International Prognostic Score with seven parameters. Methods In the present study, we investigated if pretherapeutic Hgb concentration added prognostic information to the NCCN-IPI in diffuse large B-cell lymphoma. We included patients from the Danish Lymphoma Registry (LYFO; N = 3499) and from the Molecular Epidemiology Resource (MER; N = 1225), Mayo Clinic and University of Iowa. Four sex-specific Hgb groups were defined: below transfusion threshold, from transfusion threshold to below lower limit of normal, from lower limit of normal to the population mean, and above the mean. We used multivariable Cox regression to estimate the hazard rate ratios (HR) and 95% CIs for overall survival (OS) and event-free survival (EFS), adjusting for sex, NCCN-IPI, comorbidity, and rituximab treatment. Results Approximately half of the patients had Hgb levels below the lower limit of normal. Compared to patients with Hgb levels above the mean, an inferior OS was directly correlated with lower pretreatment Hgb within the predefined groups (HR=1.23, HR=1.51, and HR=2.05, respectively). These findings were validated in the MER. Conclusion Based on multivariable analysis, lower pretreatment Hgb, even within the normal range but below the mean, added prognostic information to established indices such as the NCCN-IPI and the Charlson comorbidity index.
Collapse
Affiliation(s)
- Michael R Clausen
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
| | - Matthew J Maurer
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | | | - Thomas S Larsen
- Department of Hematology, Odense University Hospital, Odense, Denmark
| | - Bodil Himmelstrup
- Department of Hematology, Zealand University Hospital, Roskilde, Denmark
| | | | - Brian K Link
- Department of Internal Medicine, University of Iowa, Iowa City, IA, USA
| | - Andrew L Feldman
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - Susan L Slager
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | | | | | | | - Jakob Madsen
- Department of Hematology, Aalborg University Hospital, Aalborg, Denmark
| | | | | | - James R Cerhan
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | - Mette Nørgaard
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
| | - Francesco D'Amore
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
| |
Collapse
|
12
|
Barrenetxea Lekue C, Grasso Cicala S, Leppä S, Stauffer Larsen T, Herráez Rodríguez S, Alonso Caballero C, Jørgensen JM, Toldbod H, Leal Martínez I, D'Amore F. Pixantrone beyond monotherapy: a review. Ann Hematol 2019; 98:2025-2033. [PMID: 31312929 PMCID: PMC6700039 DOI: 10.1007/s00277-019-03749-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2019] [Accepted: 06/20/2019] [Indexed: 01/12/2023]
Abstract
Outcomes for patients with non-Hodgkin's lymphoma (NHL) that proves refractory to treatment remain poor. Treatment of such patients is individualized and can include enrolment in a clinical trial of novel agents or use of one of a wide array of drug regimens. Initial treatment with anthracyclines such as doxorubicin limits options at later stages of treatment because of anthracycline-related cumulative cardiotoxicity. The aza-anthracenedione pixantrone was developed to reduce the likelihood of cardiotoxicity without compromising efficacy and is currently conditionally approved for use as monotherapy in patients with multiply-relapsed or refractory aggressive B cell NHL. The use of pixantrone in combination therapy, often to replace doxorubicin or mitoxantrone, has or is currently being investigated in numerous studies in patients with aggressive or indolent NHL and is the focus of this review. These include the R-CPOP regimen (rituximab, cyclophosphamide, pixantrone, vincristine, prednisone) for aggressive NHL in the first-line setting, including a study in elderly patients with limited cardiac function, and for patients with relapsed NHL with prior anthracycline exposure; the PSHAP regimen (pixantrone, cytarabine, prednisone, cisplatin), also in the latter setting; the PREBen/PEBen regimen (pixantrone, bendamustine and etoposide with or without rituximab) as salvage therapy; and pixantrone in combination with fludarabine, dexamethasone, and rituximab (FPD-R) for relapsed indolent NHL.
Collapse
Affiliation(s)
| | | | - Sirpa Leppä
- Department of Oncology, Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki, Helsinki, Finland
| | | | | | - Clara Alonso Caballero
- Hospital Universitario Basurto, Avenida de Montevideo, 18, 48013, Bilbao, Vizcaya, Spain
| | - Judit M Jørgensen
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
| | - Helle Toldbod
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
| | - Irene Leal Martínez
- Hospital Universitario Basurto, Avenida de Montevideo, 18, 48013, Bilbao, Vizcaya, Spain
| | - Francesco D'Amore
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
| |
Collapse
|
13
|
Lugtenburg EJ, Brown P, van der Holt B, D'Amore F, Koene HR, de Jongh E, Fijnheer R, Loosveld O, Böhmer LH, Pruijt H, Verhoef G, Hoogendoorn M, Bilgin Y, Nijland M, Lam KH, de Keizer B, de Jong D, Zijlstra JM. Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.7507] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7507 Background: This randomized phase III trial assessed whether intensification of rituximab (R) during the first 4 cycles of R-CHOP can improve outcome of diffuse large B-cell lymphoma (DLBCL) patients compared with standard R-CHOP. Patients in complete remission (CR) after induction treatment were randomized between rituximab maintenance and observation. Intensification of rituximab was not more effective than standard R-CHOP, showing same CR-rates and progression free survival after induction (ASCO 2016 # 7504). Here, we report the results of the second randomization for rituximab maintenance therapy. Methods: Patients in CR after R-CHOP were randomized between 24 months of rituximab maintenance 375 mg/m2 intravenous every 8 weeks (n = 199 ) or observation (n = 199). CT scans were performed at 6, 12, 18 and 24 months in both arms. The primary endpoint was disease free survival (DFS) from maintenance randomization. Secondary endpoints were overall survival (OS) and adverse events (AEs). ( www.trialregister.nl NTR1014). Results: Median age was 65 years (range 31-80), 48% were 66 years or older and 49% were male. The majority of patients (54%) had a high-intermediate or high aa-IPI score. After a median follow-up of 79.9 months (maximum 125.7 months), the 5-year DFS rate was 79% for rituximab maintenance versus 74% for observation. This difference was not statistically significant, with a hazard ratio of 0.83 (95% confidence interval 0.57-1.19, p= 0.31, adjusted for age and aa-IPI). The secondary endpoint OS was also not significantly different (85% versus 83% at 5 years). No clinical subgroup benefited from rituximab maintenance. Toxicity was mild. Among patients who received rituximab maintenance CTCAE grade 3 and 4 AEs were reported in 17% and 6% of patients, respectively. Infection was the most frequent AE, a grade 3 infection occurred in 6% of patients. Neutropenia was seen in 1% (grade 3) and 3% (grade 4) of patients. Conclusions: Rituximab maintenance therapy provides no additional benefit for DLBCL patients in first CR after R-CHOP. Clinical trial information: www.trialregister.nl NTR1014.
Collapse
Affiliation(s)
- Elly J. Lugtenburg
- Erasmus MC Cancer Institute, Department of Hematology, Rotterdam, Netherlands
| | - Peter Brown
- Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Bronno van der Holt
- HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
| | - Francesco D'Amore
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
| | - Harry R Koene
- Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, Netherlands
| | - Eva de Jongh
- Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands
| | - Rob Fijnheer
- Department of Hematology, Meander MC, Amersfoort, Netherlands
| | - Olaf Loosveld
- Department of Hematology, Amphia Hospital, Breda, Netherlands
| | - Lara H Böhmer
- Department of Hematology, Haga Teaching Hospital, The Hague, Netherlands
| | - Hans Pruijt
- Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands
| | - Gregor Verhoef
- Department of Hematology, University Hospitals, Leuven, Belgium
| | - Mels Hoogendoorn
- Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, Netherlands
| | - Yavuz Bilgin
- Department of Internal Medicine, Admiraal de Ruyter Hospital, Goes, Netherlands
| | - Marcel Nijland
- Department of Hematology, University Medical Center Groningen, Groningen, Netherlands
| | - King H Lam
- HOVON Pathology Facility and Biobank (HOP), Department of Pathology, Erasmus MC, Rotterdam, Netherlands
| | - Bart de Keizer
- Department of Nuclear Medicine, UMC Utrecht, Utrecht, Netherlands
| | - Daphne de Jong
- HOVON Pathology Facility and Biobank (HOP), Department of Pathology, Amsterdam UMC, location VUmc, Amsterdam, Netherlands
| | - Josee M Zijlstra
- Department of Hematology, Amsterdam UMC, Vrije Universiteit Cancer Center, Amsterdam, Netherlands
| |
Collapse
|
14
|
Tolomeo D, Rubegni A, Severino M, Pochiero F, Bruno C, Cassandrini D, Madeo A, Doccini S, Pedemonte M, Rossi A, D'Amore F, Donati M, Di Rocco M, Santorelli F, Nesti C. Clinical and neuroimaging features of the m.10197G>A mtDNA mutation: New case reports and expansion of the phenotype variability. J Neurol Sci 2019; 399:69-75. [DOI: 10.1016/j.jns.2019.02.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2018] [Revised: 02/01/2019] [Accepted: 02/05/2019] [Indexed: 12/20/2022]
|
15
|
Trotman J, Fosså A, Federico M, Stevens L, Kirkwood A, Clifton-Hadley L, Patrick P, Berkahn L, D'Amore F, Enblad G, Luminari S, Radford J, Barrington S, Johnson P. RESPONSE-ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE-ESCALATION AFTER a NEGATIVE INTERIM PET SCAN (CRUK/07/033). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_53] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- J. Trotman
- Haematology, Concord Repatriation General Hospital; University of Sydney; Concord Australia
| | - A. Fosså
- Medical Oncology; Oslo University Hospital; Oslo Norway
| | - M. Federico
- Diagnostic Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Missouri Italy
| | - L. Stevens
- Cancer Trials Centre; Cancer Research UK and University College London; London UK
| | - A. Kirkwood
- Cancer Trials Centre; Cancer Research UK and University College London; London UK
| | - L. Clifton-Hadley
- Cancer Trials Centre; Cancer Research UK and University College London; London UK
| | - P. Patrick
- Cancer Trials Centre; Cancer Research UK and University College London; London UK
| | - L. Berkahn
- Haematology; Auckland City Hospital; Auckland New Zealand
| | - F. D'Amore
- Haematology; Aarhus University Hospital; Aarhus C Denmark
| | - G. Enblad
- Immunology, Genetics and Pathology; Uppsala University; Uppsala Sweden
| | - S. Luminari
- Arcispedale Santa Maria Nuova; Istituti di Ricovero e Cura a Carattere Scientifico; Reggio Emilia Italy
| | - J. Radford
- Medical Oncology; Christie Hospital; Manchester UK
| | - S.F. Barrington
- The PET Imaging Centre, King's College London; King's Health Partners, St. Thomas' Hospital; London UK
| | - P. Johnson
- Cancer Research UK Centre; University of Southampton; Southampton UK
| |
Collapse
|
16
|
De Simone F, Artaxo P, Bencardino M, Cinnirella S, Carbone F, D'Amore F, Dommergue A, Feng XB, Gencarelli CN, Hedgecock IM, Landis MS, Sprovieri F, Suzuki N, Wängberg I, Pirrone N. Particulate-phase mercury emissions from biomass burning and impact on resulting deposition: a modelling assessment. Atmos Chem Phys 2017. [PMID: 30079082 DOI: 10.5194/acp-2016-685] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
Mercury (Hg) emissions from biomass burning (BB) are an important source of atmospheric Hg and a major factor driving the interannual variation of Hg concentrations in the troposphere. The greatest fraction of Hg from BB is released in the form of elemental Hg(Hg(g)0) . However, little is known about the fraction of Hg bound to particulate matter (HgP) released from BB, and the factors controlling this fraction are also uncertain. In light of the aims of the Minamata Convention to reduce intentional Hg use and emissions from anthropogenic activities, the relative importance of Hg emissions from BB will have an increasing impact on Hg deposition fluxes. Hg speciation is one of the most important factors determining the redistribution of Hg in the atmosphere and the geographical distribution of Hg deposition. Using the latest version of the Global Fire Emissions Database (GFEDv4.1s) and the global Hg chemistry transport model, ECHMERIT, the impact of Hg speciation in BB emissions, and the factors which influence speciation, on Hg deposition have been investigated for the year 2013. The role of other uncertainties related to physical and chemical atmospheric processes involving Hg and the influence of model parametrisations were also investigated, since their interactions with Hg speciation are complex. The comparison with atmospheric HgP concentrations observed at two remote sites, Amsterdam Island (AMD) and Manaus (MAN), in the Amazon showed a significant improvement when considering a fraction of HgP from BB. The set of sensitivity runs also showed how the quantity and geographical distribution of HgP emitted from BB has a limited impact on a global scale, although the inclusion of increasing fractions HgP does limit Hg(g)0 availability to the global atmospheric pool. This reduces the fraction of Hg from BB which deposits to the world's oceans from 71 to 62 %. The impact locally is, however, significant on northern boreal and tropical forests, where fires are frequent, uncontrolled and lead to notable Hg inputs to local ecosystems. In the light of ongoing climatic changes this effect could be potentially be exacerbated in the future.
Collapse
Affiliation(s)
- Francesco De Simone
- CNR-Institute of Atmospheric Pollution Research, Division of Rende, UNICAL-Polifunzionale, 87036 Rende, Italy
| | | | - Mariantonia Bencardino
- CNR-Institute of Atmospheric Pollution Research, Division of Rende, UNICAL-Polifunzionale, 87036 Rende, Italy
| | - Sergio Cinnirella
- CNR-Institute of Atmospheric Pollution Research, Division of Rende, UNICAL-Polifunzionale, 87036 Rende, Italy
| | - Francesco Carbone
- CNR-Institute of Atmospheric Pollution Research, Division of Rende, UNICAL-Polifunzionale, 87036 Rende, Italy
| | - Francesco D'Amore
- CNR-Institute of Atmospheric Pollution Research, Division of Rende, UNICAL-Polifunzionale, 87036 Rende, Italy
| | | | - Xin Bin Feng
- Institute of Geochemistry, State Key Laboratory of Environmental Geochemistry, Chinese Academy of Sciences, Guiyang, China
| | - Christian N Gencarelli
- CNR-Institute of Atmospheric Pollution Research, Division of Rende, UNICAL-Polifunzionale, 87036 Rende, Italy
| | - Ian M Hedgecock
- CNR-Institute of Atmospheric Pollution Research, Division of Rende, UNICAL-Polifunzionale, 87036 Rende, Italy
| | - Matthew S Landis
- Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, USA
| | - Francesca Sprovieri
- CNR-Institute of Atmospheric Pollution Research, Division of Rende, UNICAL-Polifunzionale, 87036 Rende, Italy
| | - Noriuki Suzuki
- National Institute for Environmental Studies (NIES), Ministry of Environment, Okinawa, Japan
| | - Ingvar Wängberg
- IVL, Swedish Environmental Research Inst. Ltd., Göteborg, Sweden
| | - Nicola Pirrone
- CNR-Institute of Atmospheric Pollution Research, Area della Ricerca di Roma 1, Via Salaria km 29 300, Monterotondo, 00015 Rome, Italy
| |
Collapse
|
17
|
Bouska A, Zhang W, Gong Q, Iqbal J, Scuto A, Vose J, Ludvigsen M, Fu K, Weisenburger DD, Greiner TC, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Delabie J, Jaffe ES, Braziel RM, Connors JM, Wu CI, Staudt LM, D'Amore F, McKeithan TW, Chan WC. Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. Leukemia 2017; 31:83-91. [PMID: 27389057 PMCID: PMC5214175 DOI: 10.1038/leu.2016.175] [Citation(s) in RCA: 67] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Revised: 05/25/2016] [Accepted: 05/27/2016] [Indexed: 12/31/2022]
Abstract
Follicular lymphoma (FL) is typically an indolent disease, but 30-40% of FL cases transform into an aggressive lymphoma (tFL) with a poor prognosis. To identify the genetic changes that drive this transformation, we sequenced the exomes of 12 cases with paired FL and tFL biopsies and identified 45 recurrently mutated genes in the FL-tFL data set and 39 in the tFL cases. We selected 496 genes of potential importance in transformation and sequenced them in 23 additional tFL cases. Integration of the mutation data with copy-number abnormality (CNA) data provided complementary information. We found recurrent mutations of miR-142, which has not been previously been reported to be mutated in FL/tFL. The genes most frequently mutated in tFL included KMT2D (MLL2), CREBBP, EZH2, BCL2 and MEF2B. Many recurrently mutated genes are involved in epigenetic regulation, the Janus-activated kinase-signal transducer and activator of transcription (STAT) or the nuclear factor-κB pathways, immune surveillance and cell cycle regulation or are TFs involved in B-cell development. Of particular interest are mutations and CNAs affecting S1P-activated pathways through S1PR1 or S1PR2, which likely regulate lymphoma cell migration and survival outside of follicles. Our custom gene enrichment panel provides high depth of coverage for the study of clonal evolution or divergence.
Collapse
Affiliation(s)
- Alyssa Bouska
- Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
| | - Weiwei Zhang
- Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
| | - Qiang Gong
- Department of Pathology, City of Hope National Medical Center, Duarte, CA
| | - Javeed Iqbal
- Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
| | - Anna Scuto
- Department of Pathology, City of Hope National Medical Center, Duarte, CA
| | - Julie Vose
- Division of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE
| | | | - Kai Fu
- Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
| | | | - Timothy C. Greiner
- Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
| | - Randy D. Gascoyne
- Center for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - Andreas Rosenwald
- Institute of Pathology, University of Würzburg, and Comprehensive Cancer Center Mainfranken, Würzburg, Germany
| | - German Ott
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
| | - Elias Campo
- Hematopathology Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Lisa M. Rimsza
- Department of Pathology, University of Arizona, Tucson, AZ
| | - Jan Delabie
- Department of Pathology, University of Toronto, Toronto, Canada
| | - Elaine S. Jaffe
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD
| | | | - Joseph M. Connors
- Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - Chung-I Wu
- Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, P.R. China
- Department of Ecology and Evolution, University of Chicago, Chicago, IL, 60637, USA
| | - Louis M. Staudt
- Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
| | | | | | - Wing C. Chan
- Department of Pathology, City of Hope National Medical Center, Duarte, CA
| |
Collapse
|
18
|
Lugtenburg PJ, de Nully Brown P, van der Holt B, D'Amore F, Koene HR, Berenschot HW, Fijnheer R, Loosveld O, Bohmer LH, Pruijt H, Verhoef G, Hoogendoorn M, de Kan R, Van Imhoff GW, van Hooije C, Lam KH, de Keizer B, de Jong D, Hoekstra OS, Zijlstra JM. Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.7504] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Bronno van der Holt
- HOVON Data Center, Erasmus MC Cancer Institute-Clinical Trial Center, Rotterdam, Netherlands
| | - Francesco D'Amore
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
| | - Harry R Koene
- Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, Netherlands
| | | | - Rob Fijnheer
- Department of Hematology, Meander MC, Amersfoort, Netherlands
| | - Olaf Loosveld
- Department of Hematology, Amphia Hospital, Breda, Netherlands
| | - Lara H Bohmer
- Department of Hematology, Haga Teaching Hospital, The Hague, Netherlands
| | - Hans Pruijt
- Jeroen Bosch Hospital, Hertogenbosch, Netherlands
| | - Gregor Verhoef
- Department of Hematology, University Hospital Leuven, Leuven, Belgium
| | - Mels Hoogendoorn
- Department of Hematology, Medical Center Leeuwarden, Leeuwarden, Netherlands
| | - Romko de Kan
- Department of Internal Medicine, Admiraal de Ruijter Hospital, Goes, Netherlands
| | | | - Christel van Hooije
- HOVON Data Center, Erasmus MC Cancer Institute, Clinical Trial Center, Rotterdam, Netherlands
| | - King H Lam
- Department of Pathology, Erasmus MC, Rotterdam, Netherlands
| | - Bart de Keizer
- Department of Nuclear Medicine, UMC Utrecht, Utrecht, Netherlands
| | - Daphne de Jong
- Department of Pathology, VU University Medical Center, Amsterdam, Netherlands
| | - Otto S. Hoekstra
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands
| | - Josee M Zijlstra
- Department of Hematology, VU University Medical Center, Amsterdam, Netherlands
| |
Collapse
|
19
|
Trumper LH, Wulf G, Ziepert M, D'Amore F, Held G, Greil R, Tournilhac O, Relander T, Viardot A, Wilhelm M, Zijlstra JM, Kluin-Nelemans JC, Nickelsen M, Braulke F, Altmann B, Rosenwald A, Gaulard P, Loeffler M, Pfreundschuh M, Schmitz N. Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.7500] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Gerald Wulf
- University Medicine Goettingen, Goettingen, Germany
| | - Marita Ziepert
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
| | | | - Gerhard Held
- Saarland University Medical School, Homburg, Germany
| | - Richard Greil
- Paracelsus Medical University Salzburg, Salzburg, Austria
| | - Olivier Tournilhac
- Service d'Hématologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | - Thomas Relander
- Department of Oncology, Lund University Hospital, Lund, Sweden
| | - Andreas Viardot
- Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany
| | | | - Josee M Zijlstra
- Department of Hematology, VU University Medical Center, Amsterdam, Netherlands
| | | | | | | | - Bettina Altmann
- Institute for Medical Informatics, Statistics and Epidemology, Leipzig University, Leipzig, Germany
| | | | | | - Markus Loeffler
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
| | | | | | | |
Collapse
|
20
|
Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, Brun E, Hjorthaug K, Viney ZN, Pike LC, Federico M, Luminari S, Radford J, Trotman J, Fosså A, Berkahn L, Molin D, D'Amore F, Sinclair DA, Smith P, O'Doherty MJ, Stevens L, Johnson PW. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood 2016; 127:1531-8. [PMID: 26747247 DOI: 10.1182/blood-2015-11-679407] [Citation(s) in RCA: 106] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2015] [Accepted: 12/26/2015] [Indexed: 02/01/2023] Open
Abstract
International guidelines recommend that positron emission tomography-computed tomography (PET-CT) should replace CT in Hodgkin lymphoma (HL). The aims of this study were to compare PET-CT with CT for staging and measure agreement between expert and local readers, using a 5-point scale (Deauville criteria), to adapt treatment in a clinical trial: Response-Adapted Therapy in Advanced Hodgkin Lymphoma (RATHL). Patients were staged using clinical assessment, CT, and bone marrow biopsy (RATHL stage). PET-CT was performed at baseline (PET0) and after 2 chemotherapy cycles (PET2) in a response-adapted design. PET-CT was reported centrally by experts at 5 national core laboratories. Local readers optionally scored PET2 scans. The RATHL and PET-CT stages were compared. Agreement among experts and between expert and local readers was measured. RATHL and PET0 stage were concordant in 938 (80%) patients. PET-CT upstaged 159 (14%) and downstaged 74 (6%) patients. Upstaging by extranodal disease in bone marrow (92), lung (11), or multiple sites (12) on PET-CT accounted for most discrepancies. Follow-up of discrepant findings confirmed the PET characterization of lesions in the vast majority. Five patients were upstaged by marrow biopsy and 7 by contrast-enhanced CT in the bowel and/or liver or spleen. PET2 agreement among experts (140 scans) with a κ (95% confidence interval) of 0.84 (0.76-0.91) was very good and between experts and local readers (300 scans) at 0.77 (0.68-0.86) was good. These results confirm PET-CT as the modern standard for staging HL and that response assessment using Deauville criteria is robust, enabling translation of RATHL results into clinical practice.
Collapse
Affiliation(s)
- Sally F Barrington
- PET Imaging Centre, Division of Imaging Sciences and Biomedical Engineering, King's College London, King's Health Partners, St. Thomas' Hospital, London, United Kingdom
| | - Amy A Kirkwood
- Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom
| | | | - Michael J Fulham
- Department of Molecular Imaging (PET-CT), Royal Prince Alfred Hospital, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia
| | - Thomas H Roberts
- Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom
| | | | - Eva Brun
- Department of Oncology and Radiation Physics, Skane University Hospital, Lund University, Lund, Sweden
| | - Karin Hjorthaug
- Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark
| | - Zaid N Viney
- Department of Radiology, Guy's and St. Thomas' National Health Service (NHS) Foundation Trust, London, United Kingdom
| | - Lucy C Pike
- PET Imaging Centre, Division of Imaging Sciences and Biomedical Engineering, King's College London, King's Health Partners, St. Thomas' Hospital, London, United Kingdom
| | - Massimo Federico
- Oncology Unit, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - Stefano Luminari
- Oncology Unit, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - John Radford
- The University of Manchester and the Christie NHS Foundation Trust, Manchester, United Kingdom
| | - Judith Trotman
- Sydney Medical School, University of Sydney, Sydney, Australia; Concord, Repatriation General Hospital, Sydney, Australia
| | - Alexander Fosså
- Department of Oncology, Norwegian Radium Hospital, Oslo, Norway
| | - Leanne Berkahn
- Haematology, Auckland City Hospital, Auckland, New Zealand
| | - Daniel Molin
- Department of Genetics and Pathology, Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden
| | | | - Donald A Sinclair
- PET Imaging Centre, Division of Imaging Sciences and Biomedical Engineering, King's College London, King's Health Partners, St. Thomas' Hospital, London, United Kingdom
| | - Paul Smith
- Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom
| | - Michael J O'Doherty
- PET Imaging Centre, Division of Imaging Sciences and Biomedical Engineering, King's College London, King's Health Partners, St. Thomas' Hospital, London, United Kingdom
| | - Lindsey Stevens
- Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom
| | - Peter W Johnson
- Cancer Research UK Centre, University of Southampton, Southampton, United Kingdom
| |
Collapse
|
21
|
Shiroishi MS, Cen SY, Tamrazi B, D'Amore F, Lerner A, King KS, Kim PE, Law M, Hwang DH, Boyko OB, Liu CSJ. Predicting Meningioma Consistency on Preoperative Neuroimaging Studies. Neurosurg Clin N Am 2016; 27:145-54. [PMID: 27012379 DOI: 10.1016/j.nec.2015.11.007] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
This article provides an overview of the neuroimaging literature focused on preoperative prediction of meningioma consistency. A validated, noninvasive neuroimaging method to predict tumor consistency can provide valuable information regarding neurosurgical planning and patient counseling. Most of the neuroimaging literature indicates conventional MRI using T2-weighted imaging may be helpful to predict meningioma consistency; however, further rigorous validation is necessary. Much less is known about advanced MRI techniques, such as diffusion MRI, MR elastography (MRE), and MR spectroscopy. Of these methods, MRE and diffusion tensor imaging appear particularly promising.
Collapse
Affiliation(s)
- Mark S Shiroishi
- Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
| | - Steven Y Cen
- Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Benita Tamrazi
- Pediatric Neuroradiology, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA
| | - Francesco D'Amore
- Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Alexander Lerner
- Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Kevin S King
- Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Paul E Kim
- Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Meng Law
- Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Darryl H Hwang
- Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Orest B Boyko
- Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Chia-Shang J Liu
- Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| |
Collapse
|
22
|
D'Amore F, Bencardino M, Cinnirella S, Sprovieri F, Pirrone N. Data quality through a web-based QA/QC system: implementation for atmospheric mercury data from the global mercury observation system. Environ Sci Process Impacts 2015; 17:1482-91. [PMID: 26174740 DOI: 10.1039/c5em00205b] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
The overall goal of the on-going Global Mercury Observation System (GMOS) project is to develop a coordinated global monitoring network for mercury, including ground-based, high altitude and sea level stations. In order to ensure data reliability and comparability, a significant effort has been made to implement a centralized system, which is designed to quality assure and quality control atmospheric mercury datasets. This system, GMOS-Data Quality Management (G-DQM), uses a web-based approach with real-time adaptive monitoring procedures aimed at preventing the production of poor-quality data. G-DQM is plugged on a cyberinfrastructure and deployed as a service. Atmospheric mercury datasets, produced during the first-three years of the GMOS project, are used as the input to demonstrate the application of the G-DQM and how it identifies a number of key issues concerning data quality. The major issues influencing data quality are presented and discussed for the GMOS stations under study. Atmospheric mercury data collected at the Longobucco (Italy) station is used as a detailed case study.
Collapse
Affiliation(s)
- Francesco D'Amore
- CNR-Institute of Atmospheric Pollution Research, Division of Rende, Italy
| | | | | | | | | |
Collapse
|
23
|
O'Connor OA, Bhagat G, Ganapathi K, Pedersen MB, D'Amore F, Radeski D, Bates SE. Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice. Clin Cancer Res 2015; 20:5240-54. [PMID: 25320373 DOI: 10.1158/1078-0432.ccr-14-2020] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Despite enormous advances in our understanding of aggressive lymphomas, it is clear that progress in the peripheral T-cell lymphomas (PTCL) has lagged well behind other B-cell malignancies. Although there are many reasons for this, the one commonly cited notes that the paradigms for diffuse large B-cell lymphoma (DLBCL) were merely applied to all patients with PTCL, the classic "one-size-fits-all" approach. Despite these challenges, progress is being made. Recently, the FDA has approved four drugs for patients with relapsed/refractory PTCL over the past 5 years, and if one counts the recent Japanese approval of the anti-CCR4 monoclonal antibody for patients with adult T-cell leukemia/lymphoma, five drugs have been approved worldwide. These efforts have led to the initiation of no fewer than four randomized clinical studies exploring the integration of these new agents into standard CHOP (cyclophosphamide-Adriamycin-vincristine-prednisone)-based chemotherapy regimens for patients with newly diagnosed PTCL. In addition, a new wave of studies are exploring the merits of novel drug combinations in the disease, an effort to build on the obvious single-agent successes. What has emerged most recently is the recognition that the PTCL may be a disease-characterized by epigenetic dysregulation, which may help explain its sensitivity to histone deacetylase (HDAC) inhibitors, and open the door for even more creative combination approaches. Nonetheless, advances made over a relatively short period of time are changing how we now view these diseases and, hopefully, have poised us to finally improve its prognosis. See all articles in this CCR Focus section, "Paradigm Shifts in Lymphoma."
Collapse
Affiliation(s)
- Owen A O'Connor
- Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, The New York Presbyterian Hospital, New York, New York.
| | - Govind Bhagat
- Division of Hematopathology, Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York
| | - Karthik Ganapathi
- Division of Hematopathology, Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York
| | | | - Francesco D'Amore
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
| | - Dejan Radeski
- Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, The New York Presbyterian Hospital, New York, New York
| | - Susan E Bates
- Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland
| |
Collapse
|
24
|
Ludvigsen M, Kamper P, Sørensen BS, Møller MB, Bendix K, Hamilton-Dutoit SJ, Alsner J, D'Amore F, Honoré B. Differential protein expression of peroxiredoxin-1 in classical Hodgkin Lymphoma: a possible correlation to clinical behaviour. Hematol Oncol 2014; 33:253-5. [PMID: 25236407 DOI: 10.1002/hon.2157] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2014] [Accepted: 07/09/2014] [Indexed: 11/06/2022]
Affiliation(s)
- Maja Ludvigsen
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
| | - Peter Kamper
- Department of Haematology, Arhus University Hospital, Aarhus, Denmark
| | - Brita Singers Sørensen
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
| | | | - Knud Bendix
- Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark
| | | | - Jan Alsner
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - Francesco D'Amore
- Department of Haematology, Arhus University Hospital, Aarhus, Denmark
| | - Bent Honoré
- Department of Biomedicine, Aarhus University, Aarhus, Denmark.
| |
Collapse
|
25
|
Kelsen J, Dige A, Christensen M, D'Amore F, Iversen L. Frequency and clonality of peripheral γδ T cells in psoriasis patients receiving anti-tumour necrosis factor-α therapy. Clin Exp Immunol 2014; 177:142-8. [PMID: 24635218 PMCID: PMC4089163 DOI: 10.1111/cei.12331] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/05/2014] [Indexed: 01/27/2023] Open
Abstract
Hepatosplenic γδ T cell lymphoma (HSTCL) has been observed in patients with Crohn's disease (CD) who received anti-tumour necrosis factor (TNF)-α agents and thiopurines, but only one case was reported in a psoriasis patient worldwide. This difference could be due to differences in either the nature of the inflammatory diseases or in the use of immunomodulators. We investigated the impact of anti-TNF-α agents on the level and repertoire of γδ T cells in peripheral blood from psoriasis patients. Forty-five men and 10 women who were treated with anti-TNF-α agents for psoriasis were monitored for a median 11 months for the level and clonality of γδ T cells via flow cytometry and polymerase chain reaction (PCR) analysis of T cell receptor gamma (TCR-γ) gene rearrangements. Seventeen men had a repeated analysis within 48 h of the infliximab infusion to reveal a possible expansion of γδ T cells, as observed previously in CD patients. Ten psoriasis patients who were never exposed to biologicals and 20 healthy individuals served as controls. In the majority of psoriasis patients, the level and clonal pattern of γδ T cells was remarkably stable during infliximab treatment. A single male patient repeatedly experienced a significant increase in the level of γδ T cells after infliximab infusions. A monoclonal γδ T cell repertoire in a polyclonal background tended to be more frequent in anti-TNF-α-treated patients than naive patients, suggesting that anti-TNF-α therapy may promote the clonal selection of γδ T cells in psoriasis patients.
Collapse
Affiliation(s)
- J Kelsen
- Gastro-Immuno Research Laboratory (GIRL), Department of Hepatology and Gastroenterology, Aarhus University Hospital, Randers, Denmark; Department of Medicine, Randers Regional Hospital, Randers, Denmark
| | | | | | | | | |
Collapse
|
26
|
Shiroishi MS, Castellazzi G, Boxerman JL, D'Amore F, Essig M, Nguyen TB, Provenzale JM, Enterline DS, Anzalone N, Dörfler A, Rovira À, Wintermark M, Law M. Principles of T2*-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging. J Magn Reson Imaging 2014; 41:296-313. [DOI: 10.1002/jmri.24648] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2013] [Accepted: 04/03/2014] [Indexed: 01/17/2023] Open
Affiliation(s)
- Mark S. Shiroishi
- Keck School of Medicine; University of Southern California; Los Angeles California USA
| | - Gloria Castellazzi
- Department of Industrial and Information Engineering; University of Pavia; Pavia Italy
- Brain Connectivity Center, IRCCS “C. Mondino Foundation,”; Pavia Italy
| | - Jerrold L. Boxerman
- Warren Alpert Medical School of Brown University; Providence Rhode Island USA
| | - Francesco D'Amore
- Keck School of Medicine; University of Southern California; Los Angeles California USA
- Department of Neuroradiology; IRCCS “C. Mondino Foundation,” University of Pavia; Pavia Italy
| | - Marco Essig
- University of Manitoba's Faculty of Medicine; Winnipeg Manitoba Canada
| | - Thanh B. Nguyen
- Faculty of Medicine, Ottawa University; Ottawa Ontario Canada
| | - James M. Provenzale
- Duke University Medical Center; Durham North Carolina USA
- Emory University School of Medicine; Atlanta Georgia USA
| | | | | | - Arnd Dörfler
- University of Erlangen-Nuremberg, Erlangen; Germany
| | - Àlex Rovira
- Vall d'Hebron University Hospital; Barcelona Spain
| | - Max Wintermark
- School of Medicine; University of Virginia; Charlottesville Virginia USA
| | - Meng Law
- Keck School of Medicine; University of Southern California; Los Angeles California USA
| |
Collapse
|
27
|
Sivasundaram L, Hazany S, Wagle N, Zada G, Chen TC, Lerner A, Go JL, D'Amore F, Law M, Shiroishi MS. Diffusion restriction in a non-enhancing metastatic brain tumor treated with bevacizumab - recurrent tumor or atypical necrosis? Clin Imaging 2014; 38:724-6. [PMID: 24910165 DOI: 10.1016/j.clinimag.2014.04.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2013] [Revised: 04/22/2014] [Accepted: 04/23/2014] [Indexed: 01/23/2023]
Abstract
A 38-year-old female with metastatic brain cancer developed non-enhancing, diffusion restricted lesions following bevacizumab treatment. From our review of the literature, this is the first reported case of this type of lesion. Clinicians should be wary of these lesions, as they can represent either tumor progression or necrosis/effects of chronic hypoxia from anti-angiogenic therapy. Further investigation is necessary to determine the biological mechanism and clinical significance of this type of imaging appearance.
Collapse
Affiliation(s)
| | - Saman Hazany
- Division of Neuroradiology, Department of Radiology, Keck School of Medicine of USC
| | - Naveed Wagle
- Department of Neurology, Keck School of Medicine of USC
| | - Gabriel Zada
- Department of Neurological Surgery, Keck School of Medicine of USC
| | - Thomas C Chen
- Department of Neurological Surgery, Keck School of Medicine of USC
| | - Alexander Lerner
- Division of Neuroradiology, Department of Radiology, Keck School of Medicine of USC
| | - John L Go
- Division of Neuroradiology, Department of Radiology, Keck School of Medicine of USC
| | - Francesco D'Amore
- Division of Neuroradiology, Department of Radiology, Keck School of Medicine of USC
| | - Meng Law
- Division of Neuroradiology, Department of Radiology, Keck School of Medicine of USC
| | - Mark S Shiroishi
- Division of Neuroradiology, Department of Radiology, Keck School of Medicine of USC
| |
Collapse
|
28
|
Cinnirella S, D'Amore F, Bencardino M, Sprovieri F, Pirrone N. The GMOS cyber(e)-infrastructure: advanced services for supporting science and policy. Environ Sci Pollut Res Int 2014; 21:4193-208. [PMID: 24249682 DOI: 10.1007/s11356-013-2308-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/31/2013] [Accepted: 10/28/2013] [Indexed: 05/04/2023]
Abstract
The need for coordinated, systematized and catalogued databases on mercury in the environment is of paramount importance as improved information can help the assessment of the effectiveness of measures established to phase out and ban mercury. Long-term monitoring sites have been established in a number of regions and countries for the measurement of mercury in ambient air and wet deposition. Long term measurements of mercury concentration in biota also produced a huge amount of information, but such initiatives are far from being within a global, systematic and interoperable approach. To address these weaknesses the on-going Global Mercury Observation System (GMOS) project ( www.gmos.eu ) established a coordinated global observation system for mercury as well it retrieved historical data ( www.gmos.eu/sdi ). To manage such large amount of information a technological infrastructure was planned. This high-performance back-end resource associated with sophisticated client applications enables data storage, computing services, telecommunications networks and all services necessary to support the activity. This paper reports the architecture definition of the GMOS Cyber(e)-Infrastructure and the services developed to support science and policy, including the United Nation Environmental Program. It finally describes new possibilities in data analysis and data management through client applications.
Collapse
Affiliation(s)
- S Cinnirella
- Division of Rende, CNR-Institute of Atmospheric Pollution Research, Rende, Italy,
| | | | | | | | | |
Collapse
|
29
|
Sutera S, Astolfi F, Trapani A, D'Amore F, Lodi G. Oral squamous cell carcinoma presenting as a cervical lymphadenopathy. Ann Stomatol (Roma) 2013; 4:42. [PMID: 24353817 PMCID: PMC3860238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- S Sutera
- UO Dentistry II - AO San Paolo Hospital Milan, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - F Astolfi
- UO Dentistry II - AO San Paolo Hospital Milan, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - A Trapani
- UO Dentistry II - AO San Paolo Hospital Milan, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - F D'Amore
- UO Dentistry II - AO San Paolo Hospital Milan, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - G Lodi
- UO Dentistry II - AO San Paolo Hospital Milan, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| |
Collapse
|
30
|
Astolfi F, Sutera S, Trapani A, D'Amore F, Sardella A. An unusual lesion of the palate. Ann Stomatol (Roma) 2013; 4:6. [PMID: 24353761 PMCID: PMC3860212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- F Astolfi
- OU Dentistry II - AO San Paolo Hospital Milan, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - S Sutera
- OU Dentistry II - AO San Paolo Hospital Milan, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - A Trapani
- OU Dentistry II - AO San Paolo Hospital Milan, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - F D'Amore
- OU Dentistry II - AO San Paolo Hospital Milan, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - A Sardella
- OU Dentistry II - AO San Paolo Hospital Milan, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| |
Collapse
|
31
|
D'Amore F, Astolfi F, Varoni E, Pispero A, Lodi G. An unusual lingual lesion in a little patient. Ann Stomatol (Roma) 2013; 4:12. [PMID: 24353770 PMCID: PMC3860247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- F D'Amore
- UO Dentistry II - AO San Paolo Hospital Milan, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - F Astolfi
- UO Dentistry II - AO San Paolo Hospital Milan, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - E Varoni
- UO Dentistry II - AO San Paolo Hospital Milan, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - A Pispero
- UO Dentistry II - AO San Paolo Hospital Milan, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - G Lodi
- UO Dentistry II - AO San Paolo Hospital Milan, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| |
Collapse
|
32
|
Abstract
In his work, the doctor walks a narrow line between doing too much or doing too little. This is a difficult terrain requiring a sense of balance, of solidarity and the knowledge that, in the near future, the doctor will be the main actor in changing the relationships between the medical profession and society...
Collapse
|
33
|
Wästerlid T, Brown PN, Hagberg O, Hagberg H, Pedersen LM, D'Amore F, Jerkeman M. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol 2013; 24:1879-1886. [PMID: 23446093 DOI: 10.1093/annonc/mdt058] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Standard treatment of adult Burkitt lymphoma is not defined due to the lack of randomised trials. In this situation, population-based data may represent a useful contribution in order to identify an optimal treatment strategy. PATIENTS AND METHODS The aims of this study were to investigate the outcome for adult HIV-negative BL with different chemotherapy regimens, and to assess possible improvement within the time frame of the study. The study population was identified through the Swedish and Danish lymphoma registries 2000-2009. RESULTS A total of 258 patients were identified. Since 2000, overall survival (OS) improved significantly only for younger patients (<65 years). Intensive regimens such as the Berlin-Frankfurt-Münster, hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) and cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, and cytarabine (CODOX-M/IVAC) were associated with a favourable 2-year OS of 82%, 83%, and 69%, respectively. The low-intensive CHOP/CHOEP regimens achieved a 2-year OS of 38.8%, confirming their inadequacy for the treatment of BL. In a multivariate analysis, rituximab was not significantly associated with improved OS. CONCLUSIONS In this population-based retrospective series of adult BL, intensive chemotherapy regimens were associated with favourable outcome. The impact of the addition of rituximab remains uncertain and warrants further investigation.
Collapse
Affiliation(s)
- T Wästerlid
- Department of Oncology, Skåne University Hospital, Lund, Sweden
| | - P N Brown
- Department of Haematology, Rigshospitalet, Copenhagen, Denmark
| | - O Hagberg
- Department of Tumour Epidemiology, Skåne University Hospital, Lund
| | - H Hagberg
- Department of Oncology, Akademiska University Hospital, Uppsala, Sweden
| | - L M Pedersen
- Department of Haematology, Roskilde Hospital, Roskilde
| | - F D'Amore
- Department of Haematology, Århus University Hospital, Århus, Denmark
| | - M Jerkeman
- Department of Oncology, Skåne University Hospital, Lund, Sweden.
| |
Collapse
|
34
|
Grant C, Dunleavy K, Janik JE, Shovlin M, Steinberg SM, D'Amore F, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Wilson WH. Efficacy of alemtuzumab (ALZ) in combination with dose-adjusted EPOCH (DA-EPOCH) in untreated nodal peripheral T-cell lymphoma (PTCL). J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.8051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8051 Background: The survival of patients (pts) with PTCL (excluding ALCL) is disappointing following anthracycline-based therapy and novel approaches are needed. In diffuse large B-cell lymphoma, the addition of anti-CD20 therapy to CHOP has significantly improved outcome and we investigated if in PTCL, adding ALZ – which targets CD52, expressed on most PTCLs – was feasible and improved outcome. Methods: This was a single-center phase I/II trial of ALZ, in combination with DA-EPOCH in patients with treatment-naïve CD52+ PTCL. The MTD of 30 mg ALZ was combined with DA-EPOCH for phase II evaluation resulting in an intention-to-treat population (ITTP) of 30 pts. Results: Patient (n=30) characteristics: median (range) age 50 (17-77); M:F 1:1; Stage III/IV 27 (90%); IPI ≥2 22 (73%). Histologies: ATLL 11 (37%), PTCL NOS 6 (20%), AITL 5 (16%), Hepatosplenic 3 (10%), Peripheral T NK cell 2 (7%), Other 3 (10%). At 67 months median follow-up, 11 patients were alive, 10 disease-free. Median overall (OS) and event-free survivals (EFS) were 15.4 and 6.7 months respectively. Outcome was substantially better for pts with ‘nodal’ (AITL, PTCL-NOS, Other) compared to ‘non-nodal’ (ATLL and ‘extranodal’ histologies) PTCL subtypes. 3-year OS for the two groups was 58.3% and 27.8% respectively (p=0.082); 3-yrs EFS was 50% (median 27.0 months) and 22.2% (median: 5 months) respectively (p=0.041). Half of the ‘nodal’ PTCL pts had sustained long-term complete remissions demonstrated by a plateau in the EFS curve at 27 months. There were 3 treatment related deaths: 2 from neutropenic sepsis; 1 from toxoplasma. Other toxicities included CMV and BK virus reactivation in 53% and 30% respectively. Febrile neutropenia was seen in 20% and grade 4 thrombocytopenia in 12 % of cycles. Conclusions: Although it has significant infectious toxicity, ALZ 30mg and DA-EPOCHin untreated PTCL is feasible and associated with a long-term favorable outcome in nodal but not extranodal or leukemic PTCL. A phase III study of ALZ 30mg with anthracycline-based therapy is ongoing and we await the results with interest.
Collapse
Affiliation(s)
| | - Kieron Dunleavy
- Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - John E. Janik
- Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Margaret Shovlin
- Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Seth M. Steinberg
- Biostatistics and Data Management Section, CCR, NCI, NIH, Bethesda, MD
| | | | | | | | - Elaine S. Jaffe
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD
| | - Wyndham Hopkins Wilson
- Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
| |
Collapse
|
35
|
Kelsen J, Dige A, Schwindt H, D'Amore F, Pedersen FS, Agnholt J, Christensen LA, Dahlerup JF, Hvas CL. Infliximab induces clonal expansion of γδ-T cells in Crohn's disease: a predictor of lymphoma risk? PLoS One 2011; 6:e17890. [PMID: 21483853 PMCID: PMC3069033 DOI: 10.1371/journal.pone.0017890] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2011] [Accepted: 02/13/2011] [Indexed: 12/21/2022] Open
Abstract
Background Concominant with the widespread use of combined immunotherapy in the management of Crohn's disease (CD), the incidence of hepato-splenic gamma-delta (γδ)-T cell lymphoma has increased sharply in CD patients. Malignant transformation of lymphocytes is believed to be a multistep process resulting in the selection of malignant γδ-T cell clones. We hypothesised that repeated infusion of anti-TNF-α agents may induce clonal selection and that concurrent treatment with immunomodulators further predisposes patients to γδ-T cell expansion. Methodology/Principal Findings We investigated dynamic changes in the γδ-T cells of patient with CD following treatment with infliximab (Remicade®; n = 20) or adalimumab (Humira®; n = 26) using flow cytometry. In patients with a high γδ-T cell level, the γδ-T cells were assessed for clonality. Of these 46 CD patients, 35 had a γδ-T cells level (mean 1.6%) comparable to healthy individuals (mean 2.2%), and 11 CD patients (24%) exhibited an increased level of γδ-T cells (5–15%). In the 18 patients also receiving thiopurines or methotrexate, the average baseline γδ-T cell level was 4.4%. In three male CD patients with a high baseline value, the γδ-T cell population increased dramatically following infliximab therapy. A fourth male patient also on infliximab monotherapy presented with 20% γδ-T cells, which increased to 25% shortly after treatment and was 36% between infusions. Clonality studies revealed an oligoclonal γδ-T cell pattern with dominant γδ-T cell clones. In support of our clinical findings, in vitro experiments showed a dose-dependent proliferative effect of anti-TNF-α agents on γδ-T cells. Conclusion/Significance CD patients treated with immunomodulators had constitutively high levels of γδ-T cells. Infliximab exacerbated clonal γδ-T cell expansion in vivo and induced γδ-T cell proliferation in vitro. Overall, young, male CD patients with high baseline γδ-T cell levels may be at an increased risk of developing malignant γδ-T cell lymphomas following treatment with anti-TNF-α agents.
Collapse
Affiliation(s)
- Jens Kelsen
- Gastro-Immuno Research Laboratory (GIRL), Department of Medicine V, Aarhus University Hospital, and Institute of Molecular Biology, Aarhus University, Aarhus, Denmark.
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Colivicchi F, Di Roma A, Uguccioni M, Scotti E, Ammirati F, Arcas M, Avallone A, Bonaccorso O, Germanò G, Letizia C, Manfellotto D, Minardi G, Pristipino C, D'Amore F, Di Veroli C, Fierro A, Pastorellio R, Tozzi Q, Tubaro M, Santini M, Angelico F, Azzolini P, Bellasi A, Brocco P, Calò L, Cerquetani E, De Biase L, Di Napoli M, Galati A, Gallieni M, Jesi AP, Lombardo A, Loricchio V, Menghini F, Mezzanotte R, Minutolos R, Mocini D, Patti G, Patrizi R, Pajes G, Pulignano G, Ricci RP, Ricci R, Sardella G, Strano S, Terracina D, Testa M, Tomai F, Volpes R, Volterrani M. [Secondary cardiovascular prevention after acute coronary syndrome in clinical practice]. G Ital Cardiol (Rome) 2010; 11:3S-29S. [PMID: 20873094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Secondary prevention after acute coronary syndromes should be aimed at reducing the risk of further adverse cardiovascular events, thereby improving quality of life, and lengthening survival. Despite compelling evidence from large randomized controlled trials, secondary prevention is not fully implemented in most cases after hospitalization for acute coronary syndrome. The Lazio Region (Italy) has about 5.3 million inhabitants (9% of the entire Italian population). Every year about 11 000 patients are admitted for acute coronary syndrome in hospitals of the Lazio Region. Most of these patients receive state-of-the art acute medical and interventional care during hospitalization. However, observational data suggest that after discharge acute coronary syndrome patients are neither properly followed nor receive all evidence-based treatments. This consensus document has been developed by 11 Scientific Societies of Cardiovascular and Internal Medicine in order develop a sustainable and effective clinical approach for secondary cardiovascular prevention after acute coronary syndrome in the local scenario of the Lazio Region. An evidence-based simplified decalogue for secondary cardiovascular prevention is proposed as the cornerstone of clinical intervention, taking into account regional laws and relative shortage of resources. The following appropriate interventions should be consistently applied: smoking cessation, blood pressure control (blood pressure < 130/80 mmHg), optimal lipid management (LDL cholesterol < 80 mmHg), weight and diabetes management, promotion of physical activity and rehabilitation, correct use of antiplatelet agents, beta-blockers, renin-angiotensin-aldosterone system blockers.
Collapse
Affiliation(s)
- Furio Colivicchi
- ANMCO (Associazione Nazionale Medici Cardiologi Ospedalieri) Sezione Lazio.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Jørgensen JM, Sørensen FB, Bendix K, Nielsen JL, Funder A, Karkkainen MJ, Tainola T, Sørensen AB, Pedersen FS, D'Amore F. Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas. Leuk Lymphoma 2009; 50:1647-60. [DOI: 10.1080/10428190903156729] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
38
|
Abstract
Peripheral T-cell lymphomas (PTCL) consist of many subtypes with variable clinical presentation. Long-term prognosis of most subtypes is unfavorable and novel therapeutic approaches are needed. This review attempts to summarize what is known on the feasibility and efficacy of high-dose therapy supported by stem cell transplantation (SCT) in PTCL. In patients with relapsed or refractory PTCL, the outcome of autologous SCT (ASCT) seems to be comparable to that of patients with aggressive B-cell lymphomas. Although excellent treatment results have been encountered with ASCT in patients with anaplastic large cell lymphoma (ALCL), the superiority of this approach over chemotherapy alone needs confirmation in randomized studies. In less favorable subtypes (e.g. alk-negative ALCL, PTCL not otherwise specified, enteropathy-associated T-cell lymphoma, and angioimmunoblastic T-cell lymphoma) high-dose consolidation of the first remission should be studied in prospective trials. Minimal experience is currently available on allogeneic SCT in patients with PTCL. Given the high relapse rate after ASCT in high-risk patients and potential for graft-vs.-lymphoma effect, also this approach should be studied. Due to rarity of PTCL, international collaboration is mandatory in order to study the various aspects of SCT in this patient population.
Collapse
Affiliation(s)
- Esa Jantunen
- Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
| | | |
Collapse
|
39
|
Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25:3746-52. [PMID: 17646666 DOI: 10.1200/jco.2007.11.6525] [Citation(s) in RCA: 607] [Impact Index Per Article: 35.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
PURPOSE Starting from November 2001, 260 newly diagnosed patients with Hodgkin's lymphoma (HL) were consecutively enrolled in parallel Italian and Danish prospective trials to evaluate the prognostic role of an early interim 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and the International Prognostic Score (IPS) in advanced HL, treated with conventional ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) therapy. PATIENTS AND METHODS Most patients (n = 190) presented with advanced disease (stages IIB through IVB), whereas 70 presented in stage IIA with adverse prognostic factors. All but 11 patients were treated with standard ABVD therapy followed by consolidation radiotherapy in case of bulky presentation or residual tumor mass. Conventional radiologic staging was performed at baseline. FDG-PET scan was performed at baseline and after two courses of ABVD (PET-2). No treatment change was allowed on the basis of the PET-2 results. RESULTS After a median follow-up of 2.19 years (range, 0.32 to 5.18 years), 205 patients were in continued complete remission and two patients were in partial remission. Forty-three patients progressed during therapy or immediately after, whereas 10 patients relapsed. The 2-year progression-free survival for patients with positive PET-2 results was 12.8% and for patients with negative PET-2 results was 95.0% (P < .0001). In univariate analysis, the treatment outcome was significantly associated with PET-2 (P < .0001), stage IV (P < .0001), WBC more than 15,000 (P < .0001), lymphopenia (P < .001), IPS as a continuous variable (P < .0001), extranodal involvement (P < .0001), and bulky disease (P = .012). In multivariate analyses, only PET-2 turned out to be significant (P < .0001). CONCLUSION PET-2 overshadows the prognostic value of IPS and emerges as the single most important tool for planning of risk-adapted treatment in advanced HL.
Collapse
Affiliation(s)
- Andrea Gallamini
- Department of Hematology, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Hutchings M, Loft A, Hansen M, Pedersen LM, Berthelsen AK, Keiding S, D'Amore F, Boesen AM, Roemer L, Specht L. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 2006; 91:482-9. [PMID: 16585015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/08/2023] Open
Abstract
BACKGROUND AND OBJECTIVES In order to receive the most appropriate therapy, patients with Hodgkin's lymphoma (HL) must be accurately stratified into different prognostic staging groups. Computed tomography (CT) plays a pivotal role in the conventional staging. The aim of the present study was to investigate the value of positron emission tomography using 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) and combined FDG-PET/CT for the staging of HL patients, and the impact on the choice of treatment. DESIGN AND METHODS Ninety-nine consecutive, prospectively included patients had FDG-PET and CT in their staging work-up. Sixty-one of the 99 patients had combined FDG-PET/CT. A standard of reference for each nodal region and organ was determined using all available information including scan results, histology and a minimum of one year's clinical follow-up data. The lack of a satisfactory diagnostic gold standard limits the reliability of accuracy calculations. RESULTS FDG-PET would have upstaged 19% of patients and downstaged 5% of patients, leading to a different treatment in 9% of patients. For FDG-PET/CT, the corresponding figures are 17%, 5%, and 7%. In nodal regions, the sensitivity of FDG-PET and FDG-PET/CT seemed higher than that of CT (92% and 92% vs. 83%). FDG-PET identified more false positive nodal sites than did CT and FDG-PET/CT (1.6% vs 0.7% and 0.5%). FDG-PET and FDG-PET/CT were highly sensitive for evaluating organs (86% and 73%) while CT detected 37% of involved organs. INTERPRETATION AND CONCLUSIONS FDG-PET and FDG-PET/CT have a substantial potential impact on staging and choice of treatment and the methods tend to upstage rather than downstage patients. FDG-PET and FDG-PET/CT seem to have a higher diagnostic accuracy than CT in the staging of HL. However, care should be taken so patients with an excellent prognosis and at risk of over-treatment do not receive more intensive treatment because of these staging methods.
Collapse
Affiliation(s)
- Martin Hutchings
- Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D'Amore F, Boesen AM, Berthelsen AK, Specht L. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2005; 107:52-9. [PMID: 16150944 DOI: 10.1182/blood-2005-06-2252] [Citation(s) in RCA: 603] [Impact Index Per Article: 31.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Risk-adapted lymphoma treatment requires early and accurate assessment of prognosis. This investigation prospectively assessed the value of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) after two cycles of chemotherapy for prediction of progression-free survival (PFS) and overall survival (OS) in Hodgkin lymphoma (HL). Seventy-seven consecutive, newly diagnosed patients underwent FDG-PET at staging, after two and four cycles of chemotherapy, and after completion of chemotherapy. Median follow-up was 23 months. After two cycles of chemotherapy, 61 patients had negative FDG-PET scans and 16 patients had positive scans. Eleven of 16 FDG-PET-positive patients progressed and 2 died. Three of 61 FDG-PET-negative patients progressed; all were alive at latest follow-up. Survival analyses showed strong associations between early FDG-PET after two cycles and PFS (P < .001) and OS (P < .01). For prediction of PFS, interim FDG-PET was as accurate after two cycles as later during treatment and superior to computerized tomography (CT) at all times. In regression analyses, early interim FDG-PET was stronger than established prognostic factors. Other significant prognostic factors were stage and extranodal disease. Early interim FDG-PET is a strong and independent predictor of PFS in HL. A positive early interim FDG-PET is highly predictive of progression in patients with advanced-stage or extranodal disease.
Collapse
Affiliation(s)
- Martin Hutchings
- PET and Cyclotron Unit, Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, 9, Blegdamsvej, DK-2100 Copenhagen Ø, Denmark.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Tkachenko V, Marino A, Vita F, D'Amore F, De Stefano L, Malinconico M, Rippa M, Abbate G. Spectroscopic ellipsometry study of liquid crystal and polymeric thin films in visible and near infrared. Eur Phys J E Soft Matter 2004; 14:185-192. [PMID: 15254838 DOI: 10.1140/epje/i2004-10014-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
In this work, we propose spectroscopic ellipsometry as a suitable method for measuring optical properties in soft materials, polymers and liquid crystals, specially selected for use in photonics applications. We show the results of our measurements on some multilayered samples, in the range from visible to the near-IR region, of interest for telecom applications. We point out potentialities and limits of the technique and compare the obtained results with another experimental method, the m-lines spectroscopy, and/or with existing data in the literature. The results about the optical parameters for the analysed materials (the nematic liquid crystal 5CB, one commercial and one lab made optical polymer, and an Indium Tin Oxide film) are useful and interesting by themselves. In fact, as a paradigmatic example, we briefly discuss how an incomplete knowledge of this kind of data can lead to a wrong design of a Bragg grating device. However, more than in the provided data, we put the interest of the present analysis in the warnings about spectroscopic ellipsometry utilization and eventually the necessity of getting complementary information.
Collapse
Affiliation(s)
- V Tkachenko
- INFM Unitá di Napoli c/o Dipartimento di Scienze Fisiche, Universitá di Napoli Federico II, via Cintia, Monte S'Angelo, 80126, Napoli, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
43
|
D'Amore F, Pietralunga SM, Lorusso P, Martinelli M, Zappettini A, Dal Bo E, Tassone F, Tognini P, Travagnin M. Nonlinear optical characterisation of CdS and PbS quantum dots dispersed in a glass matrix. ACTA ACUST UNITED AC 2004. [DOI: 10.1002/pssc.200304275] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
44
|
Blasi C, D'Amore F, Delle Fave G, Massa R, Reale MG, Caliumi C, Letizia C. A case of pheochromocytoma with renal artery stenosis and post-surgical watery diarrhea. Horm Res Paediatr 2002; 56:130-3. [PMID: 11847476 DOI: 10.1159/000048105] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
A 35-year-old woman was admitted to our hospital with the following complaints, headache, sweating, anxiety, dizziness, nausea, vomiting and severe hypertension. The technical images (abdominal CT, scintigraphic octreotide scan and renal arteriography) revealed the presence of a left adrenal pheochromocytoma and stenosis of the renal artery. Ten days following adrenalectomy, watery diarrhea appeared. The long-acting somatostatin analogue octreotide (LAR, 30 mg/month, i.m.), was started, and after 2 weeks diarrhea decreased and gradually disappeared. In conclusion, we were confronted with an unusual case of pheochromocytoma associated with renal artery stenosis and the appearance of watery diarrhea some days after surgical treatment. Treatment with octreotide brought about the remission of diarrhea in this patient.
Collapse
Affiliation(s)
- C Blasi
- Second Division of Internal Medicine, Hospital Sandro Pertini, Rome, Italy
| | | | | | | | | | | | | |
Collapse
|
45
|
Vairo G, Salustri A, Trambaiolo P, D'Amore F. Scurvy mimicking systemic vasculitis. Minerva Med 2002; 93:145-50. [PMID: 12032446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
An 91 years old woman was hospitalized because of lethargy, shortness of breath and diffuse subcutaneous hemorrhage of legs. Clinical features were consistent with the diagnosis of vasculitis with systemic involvement. However dermatologic characteristics of the legs, in association with malnutrition, suggested vitamin C deficiency which was confirmed by laboratory test. Ascorbic acid supplement dramatically improved her clinical symptoms. This case remarks how scurvy may mimmick a systemic vasculitis.
Collapse
Affiliation(s)
- G Vairo
- Emergency Department, Hospital Sandro Pertini, Rome, Italy.
| | | | | | | |
Collapse
|
46
|
D'Amore F, Buda CA, Magnano A, Bottari A, Consolo P, Romeo L, Giudice A. [Endoscopic treatment of a gastric phytobezoar using electrohydraulic lithotripsy: a case report]. G Chir 1998; 19:475-7. [PMID: 9882953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
The Authors report a case of spontaneous large gastric phytobezoar in an unoperated stomach and describe this pathology especially with regards to pathogenesis, diagnosis and endoscopic treatment.
Collapse
Affiliation(s)
- F D'Amore
- Cattedra di Diagnostica e Chirurgia Endoscopica, Università degli Studi di Messina
| | | | | | | | | | | | | |
Collapse
|
47
|
Krogh-Jensen M, Johansen P, D'Amore F. Primary central nervous system lymphomas in immunocompetent individuals: histology, Epstein-Barr virus genome, Ki-67 proliferation index, p53 and bcl-2 gene expression. Leuk Lymphoma 1998; 30:131-42. [PMID: 9669683 DOI: 10.3109/10428199809050936] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Epstein-Barr virus (EBV) has been detected in the large majority of HIV-related primary central nervous system lymphomas (PCNSL) suggesting a pathogenetic role of the virus. Unlike HIV-related PCNSL, conflicting data exist with regard to the presence of EBV in non immunodeficiency-related (sporadic) PCNSL. For this reason, a population based material of 41 sporadic PCNSL was analysed for the presence of EBV genome (EBER, BHLF) using RNA in situ hybridisation (RISH). Furthermore, the expression of the gene products of the bcl-2 oncogene and the p53 tumor suppressor gene and the tumor growth fraction reactive with the monoclonal antibody Ki-67 have been evaluated. All cases but two were EBV genome negative. In the two positive cases less than 5% of tumor cells showed EBER positivity. In contrast, more than 75% of cells morphologically belonging to the tumor-cell population stained positively for EBER in two cases of HIV related PCNSL. Immunostaining for the bcl-2 oncoprotein was positive in 28 (72%) of 39 cases examined. In most cases more than 75% of tumor cells showed cytoplasmic expression. Of 37 cases investigated for p53 expression, 21 (57%) stained positively. However, in the large majority of positive cases less than 10% of the neoplastic cells stained. The percentage of Ki-67 positive cells ranged between 10% and 80% with a mean of 50%. The expression of the p53 and bcl-2 oncoproteins and the growth fraction did not have any prognostic impact. We conclude that the EBV genome is rarely detected in sporadic PCNSL, indicating that a pathogenetic role of EBV is unlikely. Like extracerebral B-cell lymphomas a large fraction of PCNSL expresses the p53 and bcl-2 oncoproteins, a feature, however, which does not seem to have prognostic implications.
Collapse
|
48
|
Blasi C, D'Amore F, Levati M, Bandinelli MC. [Neuroleptic malignant syndrome: a neurologic pathology of great interest for the internist]. Ann Ital Med Int 1998; 13:111-6. [PMID: 9734143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Two cases of neuroleptic malignant syndrome are reported. Although affecting chiefly psychiatric patients, this rare, polymorphic disease should be well-known to internists, general practitioners, and emergency staff because of its high risk of fatality. Our patients, who presented without some of the main symptoms, fell in the category of incomplete variants of the syndrome, the most difficult to recognize. In both patients, computerized tomography carried out at the outset of symptoms, evidenced signs of cerebral edema, a datum never before reported. The symptomatic polymorphism, pathogenesis, differential diagnosis, and therapy of this disease are illustrated and discussed.
Collapse
Affiliation(s)
- C Blasi
- Ospedale Sandro Pertini di Roma
| | | | | | | |
Collapse
|
49
|
D'Amore F, Santoro AM, Schirripa R. [Beta blockers and heart failure]. Clin Ter 1997; 148:531-5. [PMID: 9494255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
This above paper presents a critical revision of a controversial matter: the use of the beta blockers in congestive heart failure. The authors explain the appearances pathophysiological and the potentialities therapeutic also promote an increase of the attentive follow up for a better acquaintance of the use of these drugs in the along period of it.
Collapse
Affiliation(s)
- F D'Amore
- II Divisione Medicina Interna, Ospedale Sandro Pertini di Roma
| | | | | |
Collapse
|
50
|
Bottari M, D'Amore F, Buda CA, Magnano A, Melita G, Dell'Utri P, Crescenti S, Casella G. [Stenosing esophagitis caused by Trichosporon beigelii: presentation of a rare case]. G Chir 1997; 18:344-7. [PMID: 9296595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The Authors describe a rare case of esophageal stenosis complicated by gastroesophageal reflux due to Trichosporon beigelii in the absence of a pathologic predisposition or immunodeficiency. The diagnosis was drawn by embedding membrane fragments obtained endoscopically in Sabouraud and blood-Agar cultures. The patient was treated with antimicotics, immunostimulants, inhibitors of the gastric protonic pump, prokinetics and later underwent endoscopic dilatation combined with Savary-Guillard and pneumatic dilatators of growing diameter, until complete "restitutio ad integrum" of the esophageal lumen.
Collapse
Affiliation(s)
- M Bottari
- Cattedra di Diagnostica e Chirurgia Endoscopica, Università degli Studi di Messina
| | | | | | | | | | | | | | | |
Collapse
|